Biotechnology Analysts discuss the latest developments in Thalassemia and Sickle Cell Disease (relevant companies blue‘>AGIO, BLUE, VRTX) on an Analyst/Industry conference call to be held on June 17 at 1 pm hosted by JPMorgan. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGIO:
- Agios Pharmaceuticals presents results from Phase 3 ENERGIZE study of mitapivat
- Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress
- Intellia Therapeutics appoints Brian Goff to board of directors
- Agios Pharmaceuticals reinstated with a Neutral at JPMorgan
- Updated Time: Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 at 8:40 am ET
Questions or Comments about the article? Write to editor@tipranks.com